Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Goldman, Jonathan W.
Horinouchi, Hidehito
Cho, Byoung Chul
Tomasini, Pascale
Dunbar, Martin
Hoffman, David
Parikh, Apurvasena
Blot, Vincent
Camidge, D. Ross
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Natl Canc Ctr, Tokyo, Japan
[3] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[4] Aix Marseille Univ, Hop Nord, APHM, INSERM,CNRS,CRCM,Multidisciplinary Oncol & Therap, Marseille, France
[5] AbbVie Inc, N Chicago, IL USA
[6] AbbVie Inc, South San Francisco, CA USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9013
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
    Padda, S.
    Reckamp, K.
    Koczywas, M.
    Neal, J.
    Kawashima, J.
    Kong, S.
    Xin, Y.
    Huang, D.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2142 - S2143
  • [32] Resistance mechanisms in EGFR-mutated advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with first-line osimertinib (osi) and monitoring plasma mutational load: Preliminary results of REM study
    Bonanno, L.
    Ferro, A.
    Bao, L. C.
    Marinato, G. M.
    Padovan, A.
    Zulato, E.
    Frega, S.
    Dal Maso, A.
    Pasello, G.
    Indraccolo, S.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2023, 34
  • [33] Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Spira, Alex
    Angevin, Eric
    Su, Wu-Chou
    Hong, David S.
    Strickler, John H.
    Motwani, Monica
    Dunbar, Martin
    Parikh, Apurvasena
    Noon, Elysa
    Blot, Vincent
    Wu, Jun
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (05) : 1105 - +
  • [34] A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
    Gandara, David R.
    Leighl, Natasha
    Delord, Jean-Pierre
    Barlesi, Fabrice
    Bennouna, Jaafar
    Zalcman, Gerald
    Infante, Jeffrey R.
    Reckamp, Karen L.
    Kelly, Karen
    Shepherd, Frances A.
    Mazieres, Julien
    Janku, Filip
    Gardner, Olivia S.
    Mookerjee, Bijoyesh
    Wu, Yuehui
    Cox, Donna S.
    Schramek, Dan
    Peddareddigari, Vijay
    Liu, Yuan
    D'Amelio, Anthony M., Jr.
    Blumenschein, George, Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 556 - 566
  • [35] A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non-small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
    Nakamura, Atsushi
    Saito, Ryota
    Ko, Ryo
    Azuma, Koichi
    Morita, Ryo
    Maemondo, Makoto
    Oizumi, Satoshi
    Takahashi, Kazuhisa
    Kagamu, Hiroshi
    Isobe, Takeshi
    Seike, Masahiro
    Kikuchi, Toshiaki
    Okamoto, Isamu
    Morita, Satoshi
    Asahina, Hajime
    Tanaka, Kentaro
    Sugio, Kenji
    Kobayashi, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
    Padda, Sukhmani K.
    Reckamp, Karen L.
    Koczywas, Marianna
    Neal, Joel W.
    Kawashima, Jun
    Kong, Shengchun
    Huang, Daniel B.
    Kowalski, Mark
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 105 - 115
  • [37] Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer
    Wang, Yue
    Nan, Juan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 27 - 29
  • [38] A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
    Sukhmani K. Padda
    Karen L. Reckamp
    Marianna Koczywas
    Joel W. Neal
    Jun Kawashima
    Shengchun Kong
    Daniel B. Huang
    Mark Kowalski
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 105 - 115
  • [39] Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
    Barsouk, Adam
    Elghawy, Omar
    Heidlauf, Alec
    Yu, Connie
    Yang, David
    Kurian, Martin
    Goel, Keshav
    Rushkin, Lynn
    Huang, Anran
    Voruganti, Teja
    Sun, Lova
    Singh, Aditi Puri
    Cohen, Roger B.
    Aggarwal, Charu
    Marmarelis, Melina Elpi
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
    Saito, Ryota
    Sugawara, Shunichi
    Ko, Ryo
    Azuma, Koichi
    Morita, Ryo
    Maemondo, Makoto
    Oizumi, Satoshi
    Takahashi, Kazuhisa
    Kagamu, Hiroshi
    Tsubata, Yukari
    Seike, Masahiro
    Kikuchi, Toshiaki
    Okamoto, Isamu
    Satoshi, Morita
    Asahina, Hajime
    Tanaka, Kentaro
    Sugio, Kenji
    Kobayashi, Kunihiko
    EUROPEAN JOURNAL OF CANCER, 2023, 185 : 83 - 93
12345